

A²
10. (Amended) The chimeric molecule of claim 9 wherein said immunoglobulin sequence is an IgG Fc domain.

Sub.
B2
A³
~~14. (Amended) Isolated nucleic acid [encoding the RTD polypeptide of claim 1 or the extracellular domain sequence of claim 5] comprising a nucleotide sequence encoding (a) a RTD polypeptide having at least about 80% amino acid sequence identity with native sequence RTD polypeptide comprising amino acid residues 1 to 386 of Fig. 1A (SEQ ID NO:1) or (b) an extracellular domain sequence of RTD polypeptide.~~

15. (Amended) The nucleic acid of claim 14 wherein said [nucleic acid] nucleotide sequence encodes native sequence RTD polypeptide comprising amino acid residues 1 to 386 of Fig. 1A (SEQ ID NO:1).

Please add the following claims:

---28. The nucleic acid of claim 14 wherein said encoded RTD polypeptide has at least about 90% amino acid sequence identity with the RTD polypeptide comprising amino acid residues 1 to 386 of Fig. 1A (SEQ ID NO:1).

A⁴
29. The nucleic acid of claim 14 wherein said encoded RTD polypeptide has at least about 95% amino acid sequence identity with the RTD polypeptide comprising amino acid residues 1 to 386 of Fig. 1A (SEQ ID NO:1).

30. The nucleic acid of claim 15 wherein said nucleotide sequence comprises the nucleotide coding region shown in SEQ ID NO:2.

31. The nucleic acid of claim 14 wherein said encoded extracellular domain of RTD polypeptide comprises amino acid residues 56 to 212 of Fig. 1A (SEQ ID NO:1).

32. Isolated nucleic acid comprising a nucleotide sequence

encoding a tumor necrosis factor receptor (TNFR) homolog which comprises at least a first cysteine rich domain (CRD) and a second CRD, said first CRD comprising amino acid residues 99 to 139 of Fig. 1A (SEQ ID NO:1) and said second CRD comprising amino acid residues 141 to 180 of Fig. 1A (SEQ ID NO:1).

A4
Sult
B3
33. The host cell of claim 18 which comprises a CHO cell.

34. The host cell of claim 18 which comprises *E. coli*.

35. The host cell of claim 18 which comprises a yeast cell.---

REMARKS

In the Office Action, the Examiner issued a Restriction Requirement under 35 USC 121. Applicants hereby elect to prosecute the invention embodied by the claims of Group II, claims 7-10 and 14-19, in the present application. Claims drawn to the non-elected inventions, claims 1-6, 11-13, and 20-27, have been canceled without prejudice, as shown in the amendment above.

Claims 7, 10, 14 and 15 have been amended, and claims 28-35 have been added. It is believed that added claims 28-35 are drawn to the inventions of Group II, and thereby are properly included for prosecution with the presently elected claims 7-10 and 14-19. It is further believed that the claim amendments are fully supported and do not introduce new matter. Support for the claims is found at least at pages 11, 12, 23, 24, 29, 39-42, 58-59 and Figure 1D.

Lastly, with respect to Applicants' Information Disclosure Statement filed May 22, 1998, a copy of Applicants' stamped postcard is attached to confirm that the PTO received copies of the references cited in the IDS Form 1449. Because of the number of references that Applicants already provided, it would be appreciated if there was a re-newed effort to locate the references at the PTO. If the references cannot be located, the